NEWSCheck Our Blog

Bring to the table win-win survival strategies to ensure proactive domination. At the end of the day, going forward.

https://immunotherapy.life/wp-content/uploads/2021/01/Phase-I-trial-of-Claudin-18.2-specific-chimeric-antigen-receptor-T-cells-for-advanced-gastric-and-pancreatic-adenocarcinoma.-1.png

JOURNALA phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC).

January 14, 2021by admin

https://immunotherapy.life/wp-content/uploads/2021/01/How-CAR-T-Cell-Therapy-Works-copy.jpg

INTRODUCTIONHow CAR T-Cell Therapy Works

January 14, 2021by admin

https://immunotherapy.life/wp-content/uploads/2021/01/Malaysian-Genomics-to-make-CAR-T-Cell-treatment-available-in-South-East-Asia-1.png

NEWSMalaysian Genomics to make CAR T-Cell treatment available in South-East Asia

January 6, 2021by admin

https://immunotherapy.life/wp-content/uploads/2021/01/Phase-I-Study-of-Lentiviral-Transduced-Chimeric-Antigen-Receptor-Modified-T-Cells-Recognizing-Mesothelin-in-Advanced-Solid-Cancers.png

JOURNALPhase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers

November 6, 2019by admin

https://immunotherapy.life/wp-content/uploads/2021/01/CAR-T-Therapy-A-Living-Drug-1.png

INTRODUCTIONCAR-T Therapy: A Living Drug

November 2, 2019by admin

https://immunotherapy.life/wp-content/uploads/2021/01/T-Cell-Receptor-copy.jpg

JOURNALT-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study

August 13, 2019by admin

https://immunotherapy.life/wp-content/uploads/2019/07/A-Brief-Introduction-to-CAR-T-cell-Therapy.png

INTRODUCTIONA Brief Introduction to CAR T-cell Therapy

July 10, 2019by admin

https://immunotherapy.life/wp-content/uploads/2021/01/Phase-I-trial-of-Claudin-18.2-specific-chimeric-antigen-receptor-T-cells-for-advanced-gastric-and-pancreatic-adenocarcinoma.-1.png

JOURNALPhase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma.

May 26, 2019by admin

https://immunotherapy.life/wp-content/uploads/2021/01/Regression-of-Glioblastoma-after-Chimeric-Antigen-Receptor-T-Cell-Therapy-1.png

JOURNALRegression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

December 29, 2016by admin

TREATMENTS

SUPPORT

COMPANY

Sign up for you and your loved ones to receive the latest news and updates about CAR T-Cell Immunotherapy.

https://immunotherapy.life/wp-content/uploads/2021/02/MGRC-LogoFooter.png

Copyright © 2021 Malaysian Genomics Resource Centre Berhad (652790-V). All Rights Reserved.

Copyright © 2021 Malaysian Genomics Resource Centre Berhad (652790-V). All Rights Reserved.